Abstract: Objective The purpose of this study was to investigate the short-term efficacy of terlipressin and octreotide combination in treatment of decompensated cirrhotic patients complicated by hepatorenal syndrome （HRS）. Methods A total of 66 patients with decompensated cirrhosis and HRS were enrolled in this study,and were randomly divided into combination and control groups with 33 cases in each. The patients received combination of terlipressin and octreotide or terlipressin alone therapy for one week. Results At the end of the regimen,the body mass,abdominal circumference and urine volume in patients with combination therapy were（52.6±4.7） kg,（89.6±6.5） cm and （1213.6±489.4） ml/24 h,significantly different as compared to 【（57.3±4.8） kg,（95.5±7.8）cm and （747.5±310.9） ml/24 h】 in the control （P<0.01）;serum bilirubin and albumin levels in combination group were （14.6±16.5） μmol/L and （34.5±3.4） g/L,significantly different as compared to 【（20.5±19.4） μmol/L and （29.5±3.1） g/L】 in the control（P<0.01）;blood urea nitrogen and Na+ levels in combination group were （11.6±2.3） mmol/L and （133.4±5.3） mmol/L,significantly different as compared to 【（15.4±4.3） mmol/L and （127.4±4.7） mmol/L】 in the control （P<0.01）;the changes of portal vein and splenic vein diameters as well as the thickness of spleens in the two group before and after the treatment weren’t significantly different（P>0.01）. Conclusion The administration of terlipressin and octreotide might help subside ascites,increase urine volumes,and improve the short-term quality of life in patients with decompensated liver cirrhosis and HRS.

Key words: Liver cirrhosis, Hepatorenal syndrome, Octreotide, Terlipressin, Renal function